CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.06.028

摘要/Abstract

摘要： 目的研究在经导管肝动脉化疗栓塞(TACE)术时应用CalliSpheres可载药微球化疗序贯射频消融(RFA)治疗原发性肝癌(PLC)患者的疗效。方法 2019年1月～2021年1月我院收治的PLC患者79例,被分为两组,43例观察组采用CalliSpheres可载药微球TACE序贯RFA治疗,36对照组采用常规TACE序贯RFA治疗。根据实体瘤疗效考核标准评估短期疗效,采用电化学发光分析仪检测血清甲胎蛋白(AFP)和人热休克蛋白90α(HSP90α)。随访2年,记录两组生存情况。结果在治疗后1 m末,观察组肿瘤晚期缓解、部分缓解、疾病稳定和疾病控制率分别为23.3%、46.5%、16.3%和86.1%,对照组分别为11.1%、36.1%、19.4%和66.7%,其疾病控制率差异显著(P<0.05);在治疗后3 m,观察组血清AFP和HSP90α水平分别为(87.5±14.5)μg/L和(126.1±13.3)ng/mL,均显著低于对照组【分别为(164.6±17.2)μg/L和(150.8±19.7)ng/mL,P<0.05】;在治疗期间观察组和对照组不良反应发生率分别为48.8%和50.0%,差异无统计学意义(P>0.05);观察组和对照组1 a生存率分别为83.7%和72.2%,差异无统计学意义(P>0.05),而2 a生存率分别为69.8%和47.2%,差异有统计学意义(P<0.05)。结论采用CalliSpheres可载药微球TACE序贯RFA治疗PLC患者近期疗效显著,可有效提高患者近期生存率,值得进一步探究。

关键词: 原发性肝癌, CalliSpheres可载药微球, 肝动脉化疗栓塞, 射频消融, 治疗

Abstract: Objective The aim of this study was to investigate the efficacy of transcatheter arterial chemoembolization (TACE) with CalliSpheres drug-loaded microspheres followed by radiofrequency ablation (RFA) in the treatment of patients with primary liver cancer (PLC). Methods 79 patients with PLC were enrolled in our hospital between January 2019 and January 2021, and were divided into observation (n=43) and control group (n=36), receiving TACE with CalliSpheres drug-loaded microspheres followed by RFA, or the routine TACE followed by RFA. All patients were followed-up for two years. The disease control rate in the two groups after treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors. Serum alpha-fetoprotein (AFP) and human heat shock protein 90α (HSP90α) levels were detected by electrochemiluminescence analyzer. Results At the end of one month after treatment, the complete remission, partial remission, stable disease and the total disease control rate in the observation group were 23.3%, 46.5%, 16.3% and 86.1%, while they were 11.1%, 36.1%, 19.4% and 66.7% in the control, with the latter significantly different (P<0.05) between the two groups; at the end of three months after treatment, serum AFP and HSP90α levels in the observation group were (87.5±14.5)μg/L and (126.1±13.3)ng/mL, both significantly lower than [(164.6±17.2)μg/L and (150.8±19.7)ng/mL, respectively, P<0.05] in the control; during the period of treatment, the incidence of side effects in the two groups were 48.8% and 50.0%, not significantly different (P>0.05); the one-year survival rates in the observation and control groups were 83.7% and 72.2%, not significantly different (P>0.05), while the two-year survival rates were 69.8% and 47.2%, significantly different (P<0.05). Conclusion The TACE with CalliSpheres drug-loaded microspheres followed by RFA has a definite efficacy in the treatment of patients with PLC, which might prolong the survival rates.

Key words: Hepatoma, CalliSpheres drug-loaded microspheres, Transcatheter arterial chemoembolization, Radiofrequency ablation, Therapy

刘公攀, 陈涛, 丁志刚, 任明, 郭兴军, 邵存华, 卢建树. CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 879-882.

Liu Gongpan, Chen Tao, Ding Zhigang, et al. Efficacy of transcatheter arterial chemoembolization with CalliSpheres drug-loaded microspheres followed by radiofrequency ablation in the treatment of patients with primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(6): 879-882.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Liu Z, Xu K, Jiang Y, et al. Global trend of aetiology-based primary liver cancer incidence from 1990 to 2030: a modelling study. Int J Epidemiol, 2021, 50(1):128-142.
[3] Yuan ZG, Wang ZY, Xia MY, et al. Diffusion kurtosis imaging for assessing the therapeutic response of transcatheter arterial chemoembolization in hepatocellular carcinoma. J Cancer, 2020, 11(8):2339-2347.
[4] Lee SW, Yen CL, Cheng YC, et al. The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. Medicine (Baltimore), 2022, 101(41):e30875.
[5] Feng J, Yang JH, Li JH, et al. Transcatheter arterial chemoembolisation combined with radiofrequency ablation on hepatocellular carcinoma and levels of relevant markers. J Coll Physicians Surg Pak, 2020, 30(3):259-262.
[6] Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci, 2020, 21(21):8165-8184.
[7] 中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版).中华消化外科杂志,2017,16(7):635-647.
[8] Sun M, Shang P, Bai J, et al. High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. J Clin Lab Anal, 2021, 35(2):e23633.
[9] Lee SW, Peng YC, Lien HC, et al. Clinical values of Barcelona clinic liver cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization. World J Clin Cases, 2022, 10(21):7275-7284.
[10] 乔敏,赵一鉴,张建巧,等.TACE联合RFA治疗原发性肝癌患者疗效研究. 实用肝脏病杂志,2021,24(1):119-122.
[11] 朱忠杰,王喜功,李雷,等.经导管动脉内化疗栓塞术联合索拉非尼序贯微波消融和经导管动脉内化疗栓塞术联合索拉非尼治疗肿瘤直径>5 cm肝细胞癌的前瞻性研究.中华消化外科杂志,2020,19(2):145-155.
[12] Peng N, Mao L, Tao Y, et al. Callispheres© drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients. World J Surg Oncol, 2022, 20(1):254-262.
[13] 王婵,沈长清,吴晓琼,等.表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析.实用肝脏病杂志,2022,25(2):259-262.
[14] Peng Z, Cao G, Hou Q, et al. The comprehensive analysis of efficacy and safety of CalliSpheres© drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: a multiple-center, cohort study. Oncol Res, 2020, 28(3):249-271.
[15] 吕然,刘琛志.CalliSpheres载药微球TACE序贯微波消融治疗单发直径>5cm原发性老年肝癌的临床研究.中华肿瘤防治杂志,2022,29(15):1136-1142.
[16] Duan X, Zhao G, Han X, et al. Arsenic trioxide-loaded CalliSpheres: In vitro study of drug release and antitumor activity, and in vivo study of pharmacokinetics, treatment efficacy and safety in liver cancer. Oncol Rep, 2021, 46(1):124-136.
[17] 张笑时,吕少诚,潘飞,等.甲胎蛋白水平与肿瘤总体积比值对肝癌肝移植患者预后的影响.中华肝胆外科杂志,2021,27(3):215-217.
[18] Wei W, Liu M, Ning S, et al. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma. BMC Cancer, 2020, 20(1):6-14.
[19] Qin C, Gao Y, Li J, et al. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett, 2021, 21(6):487-499.
[20] Zhang J, Feng GA, Li Y, et al. Drug-eluting bead transarterial chemoembolization with medium-sized versus small-sizedCalliSpheres microspheres in unresectable primary liver cancer. Asia Pac J Clin Oncol, 2022, 18(4):388-393.

CalliSpheres可载药微球经导管肝动脉化疗栓塞序贯射频消融治疗原发性肝癌患者疗效研究^*

Efficacy of transcatheter arterial chemoembolization with CalliSpheres drug-loaded microspheres followed by radiofrequency ablation in the treatment of patients with primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[2]	宋涛, 徐敏, 党子龙, 孙珺珺. 恩替卡韦联合α-干扰素治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 785-788.
[3]	高丽娟, 李永库, 董新颖, 杨艺宁, 冷雪君. 艾米替诺福韦治疗慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 789-792.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	曹汴川, 刘梅, 丁苹, 汤玲毓, 郭明贤, 周仙, 袁天茹, 严一凯, 黄富礼, 黄永茂. 格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 801-804.
[6]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[7]	陈雅君, 朱婧, 李璐, 何钦. 标准免疫抑制疗法联合异甘草酸镁治疗自身免疫性肝炎患者外周血B细胞和调节性B细胞变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 835-838.
[8]	杨开宁, 王梦梦, 王占坤, 陈秀秀, 肖剑, 王永丽. 注射用谷胱甘肽联合硫普罗宁治疗药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 839-842.
[9]	王新月, 周莉, 董金玲, 陈煜. 双重血浆分子吸附系统治疗肝衰竭患者应用甲磺酸萘莫司他与肝素抗凝有效性与安全性比较研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 843-846.
[10]	姜亚超, 尹力, 颜状. “改良三明治夹心法”行ESVD术治疗肝硬化并发食管胃静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 863-866.
[11]	莫春明, 黄德佳, 韦惠章, 罗江伟. TACE术治疗的原发性肝癌患者血清IL-33水平变化及其对发热的鉴别意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 887-890.
[12]	于双杰, 李元元, 毕京峰, 福军亮, 宓余强. ICIs联合TKIs治疗HBV相关肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 891-894.
[13]	刘思宏, 谢琉嘉, 周志明, 许亚春. CEUS联合MRI增强扫描早期评价射频消融治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 895-898.
[14]	楼鹏, 邓继红, 严铭一. 腹腔镜肝切除术治疗原发性肝癌患者应用右美托咪定复合布托啡诺术后镇痛效果研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 899-902.
[15]	青秀, 周沙, 刘斌. HIFU消融联合化疗治疗中晚期肝母细胞瘤小儿5年随访研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 911-914.